Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12255423 | 0.89 | CYP4F2 (0.51) | CYP4F2CYP4A11KMT2AMEN1MAPT | |
| SCHEMBL1248647 | 0.83 | SMN1; SMN2 (0.65) | CYP4F2CYP4A11KMT2AMEN1MAPT | |
| SCHEMBL1989713 | 0.83 | KMT2A (0.62) | CYP4F2CYP4A11KMT2AMEN1MAPT | |
| SCHEMBL110276 | 0.82 | CYP4F2 (0.65) | CYP4F2CYP4A11KMT2ACA12CA1 | |
| SCHEMBL177641 | 0.81 | SMN1; SMN2 (0.55) | CYP4F2CYP4A11KMT2AMEN1MAPT | |
| SCHEMBL4214607 | 0.81 | SERPINE1 (0.52) | KMT2AMEN1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL29427226 | 0.81 | CYP4F2 (0.63) | CYP4F2CYP4A11KMT2ACA12CA1 | |
| SCHEMBL28376879 | 0.81 | CYP4F2 (0.63) | CYP4F2CYP4A11KMT2ACA12CA1 | |
| SCHEMBL931171 | 0.81 | MEN1 (0.52) | CYP4F2CYP4A11KMT2AMEN1MAPT | |
| SCHEMBL31618892 | 0.81 | CYP4F2 (0.52) | CYP4F2CYP4A11KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3354648-B1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1815206-B1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2939674-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1689712-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-1492757-A1 | (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | CYP4F2 205/4885CYP4A11 65/4885KMT2A 3157/4885 |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | MAP4, TUBA3C, ABCC1 | CYP4F2 468/4885CYP4A11 377/4885KMT2A 4058/4885 |
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | CYP4F2 466/4885CYP4A11 153/4885KMT2A 609/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | CYP4F2 4735/4885CYP4A11 4378/4885KMT2A 1404/4885 |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MAP4, TUBA3C, ABCC1 | CYP4F2 468/4885CYP4A11 377/4885KMT2A 4058/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | CYP4F2 324/4885CYP4A11 53/4885KMT2A 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.